We are live on
!
Find out more
M&G plc Portfolio holdings
AUM
$20.1B
Turnover
14.5%
1-Year Est. Return
16.62%
This Fund
S&P 500
This Quarter
Est. Return
-0.47%
1 Year Est. Return
+16.62%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$19.4B
AUM Growth
-$107M
(-0.55%)
Cap. Flow
-$6.32M
Cap. Flow
% of AUM
-0.03%
Top 10 Holdings %
Top 10 Hldgs %
31.82%
Holding
423
New
51
Increased
131
Reduced
125
Closed
43
Avg Time Held Equity + Options
1.3
years
Top 10 Avg Time Held Equity + Options
1.1
years
Top 20 Avg Time Held Equity + Options
1
year
Avg Time Held Equity only
1.3
years
Top 10 Avg Time Held Equity only
1.1
years
Top 20 Avg Time Held Equity only
1
year
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AstraZeneca
AZN
|
+$811M |
| 2 |
Microsoft
MSFT
|
+$183M |
| 3 |
Intuit
INTU
|
+$152M |
| 4 |
Broadcom
AVGO
|
+$130M |
| 5 |
The Magnum Ice Cream Company N.V.
MICC
|
+$102M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$190M |
| 2 |
Elevance Health
ELV
|
+$109M |
| 3 |
CME Group
CME
|
+$92.3M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$79.9M |
| 5 |
Huazhu Hotels Group
HTHT
|
+$67.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.64% |
| 2 | Healthcare | 16.38% |
| 3 | Consumer Discretionary | 15.42% |
| 4 | Financials | 11.36% |
| 5 | Communication Services | 6.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
151
NetApp
NTAP
$42.2B
| $14M | 0.07% |
+137,421
| New | +$13.9M |
2026 Q1
0 quarters
|
|
152
FTAI Aviation
FTAI
$17.3B
| $14M | 0.07% |
+57,151
| New | +$15.1M |
2026 Q1
0 quarters
|
|
153
Freightos
CRGO
$40.7M
| $13.7M | 0.07% |
6,871,094
| – | – |
2024 Q1
8 quarters
|
|
154
Dycom Industries
DY
$7.77B
| $13.3M | 0.07% |
39,360
+443
| +1% | +$166K |
2025 Q4
1 quarter
|
|
155
Astronics
ATRO
$2.65B
| $13.3M | 0.07% |
+238,448
| New | +$14.4M |
2026 Q1
0 quarters
|
|
156
Gilead Sciences
GILD
$195B
| $13.3M | 0.07% |
95,757
-6,689
| -7% | -$937K |
2024 Q1
8 quarters
|
|
157
Flutter Entertainment
FLUT
$13.2B
| $13.1M | 0.07% |
+128,271
| New | +$18.5M |
2026 Q1
0 quarters
|
|
158
Trip.com Group
TCOM
$25.1B
| $13.1M | 0.07% |
261,593
+40,410
| +18% | +$2.36M |
2024 Q1
8 quarters
|
|
159
Texas Roadhouse
TXRH
$11.2B
| $12.9M | 0.07% |
78,002
-2,299
| -3% | -$413K |
2024 Q3
6 quarters
|
|
160
Deutsche Bank
DB
$61.7B
| $12.9M | 0.07% |
445,054
+427,241
| +2,398% | +$15M |
2025 Q3
2 quarters
|
|
161
Mobileye
MBLY
$6.32B
| $12.8M | 0.07% |
+1,825,912
| New | +$16.5M |
2026 Q1
0 quarters
|
|
162
Zimmer Biomet
ZBH
$18B
| $12.7M | 0.07% |
141,610
+18,408
| +15% | +$1.69M |
2024 Q1
8 quarters
|
|
163
BioMarin Pharmaceuticals
BMRN
$10.8B
| $12.7M | 0.07% |
226,541
+2,398
| +1% | +$140K |
2025 Q2
3 quarters
|
|
164
Thomson Reuters
TRI
$46.7B
| $12.5M | 0.06% |
+135,472
| New | +$14.3M |
2026 Q1
0 quarters
|
|
165
Alnylam Pharmaceuticals
ALNY
$31.3B
| $12.5M | 0.06% |
+37,656
| New | +$12.8M |
2026 Q1
0 quarters
|
|
166
Ryan Specialty Holdings
RYAN
$4.89B
| $12.4M | 0.06% |
+365,841
| New | +$15.6M |
2026 Q1
0 quarters
|
|
167
Workday
WDAY
$47.4B
| $12.4M | 0.06% |
+95,416
| New | +$15.1M |
2026 Q1
0 quarters
|
|
168
Wingstop
WING
$3.57B
| $12.4M | 0.06% |
+79,995
| New | +$19.2M |
2026 Q1
0 quarters
|
|
169
Voya Financial
VOYA
$8.62B
| $12.3M | 0.06% |
181,554
-2,581
| -1% | -$187K |
2024 Q1
8 quarters
|
|
170
Neurocrine Biosciences
NBIX
$13.9B
| $12.2M | 0.06% |
92,554
+955
| +1% | +$127K |
2025 Q3
2 quarters
|
|
171
Roku
ROKU
$23B
| $12.1M | 0.06% |
+127,026
| New | +$12.4M |
2026 Q1
0 quarters
|
|
172
Rhythm Pharmaceuticals
RYTM
$6.06B
| $12.1M | 0.06% |
138,567
+1,493
| +1% | +$145K |
2025 Q4
1 quarter
|
|
173
Coca-Cola Europacific Partners
CCEP
$48.2B
| $12M | 0.06% |
131,481
+14,638
| +13% | +$1.41M |
2024 Q1
8 quarters
|
|
174
Snowflake
SNOW
$118B
| $11.9M | 0.06% |
78,665
+71,098
| +940% | +$13.2M |
2024 Q1
8 quarters
|
|
175
Veeva Systems
VEEV
$50.7B
| $11.9M | 0.06% |
67,418
+64,343
| +2,092% | +$12.6M |
2024 Q1
8 quarters
|
|
Similar funds
SA
BBA
M&G plc's Q1 2026 Portfolio in Review
As of Q1 2026, M&G plc held 423 positions worth $19.4B, down 0.55% from $19.5B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
M&G plc's Q1 2026 filing shows 51 new, 131 increased, 125 reduced and 43 closed positions. Its largest new stake was AstraZeneca: 4,204,199 shares worth $817M. The largest sale was Lam Research, an estimated $190M.
By sector, the portfolio is most concentrated in Technology at 21% of assets, down from 22% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- M&G plc's largest Q1 2026 buy was AstraZeneca: 4,204,199 shares worth $817M.
- M&G plc added most to Microsoft in Q1 2026, an estimated $183M increase.
- M&G plc's biggest Q1 2026 reduction was Lam Research, cutting an estimated $190M.
- M&G plc fully exited Crown Castle in Q1 2026, selling an estimated $34M.
- M&G plc's ten largest holdings make up 32% of its $19.4B portfolio in Q1 2026.
- M&G plc opened 51 new positions and closed 43 in Q1 2026.
- M&G plc's portfolio value fell 0.55% quarter-over-quarter to $19.4B.
Based on M&G plc's 13F filing for Q1 2026, filed 13 May 2026.